KalVista Pharmaceuticals

KalVista Pharmaceuticals is a biopharmaceutical company specialising in the discovery and commercialisation of oral small molecule protease inhibitors for rare diseases with significant unmet need.

The company's lead programme targets the kallikrein-kinin system and has produced an approved oral on-demand therapy for hereditary angioedema, a rare genetic disorder characterised by recurrent attacks of tissue swelling.

KalVista's drug discovery operations are based at its Salisbury laboratories, with commercial and clinical activities conducted globally.